5:03 PM
 | 
Oct 25, 2013
 |  BC Extra  |  Top Story

FDA panel backs Gilead's sofosbuvir

FDA's Antiviral Drugs Advisory Committee voted 15-0 in favor of approval of sofosbuvir ( GS-7977) from Gilead Sciences Inc. (NASDAQ:GILD) in combination with ribavirin to treat HCV genotypes 2 and 3 infection in both treatment-naïve and treatment-experienced patients -- moving the compound a step closer to becoming the first all-oral, interferon-free regimen to be approved in the world. The committee...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >